In a nutshell This article looked at the safety and effectiveness of abemaciclib (Verzenios) plus hormonal therapy (HT) in older patients with hormone receptor-positive (HR+)/HER-2 negative (HER2-) advanced breast cancer (BC). The authors concluded that abemaciclib + HT was effective across all age groups and while higher rates of side effects...
Read More
In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...
Read More
In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...
Read More
In a nutshell This study evaluated the use of progesterone receptor status as an independent predictor of disease prognosis in patients with early breast cancer. Some background Most breast cancer cells grow in response to female hormones, such as progesterone and estrogen. Cancer response to these growth stimuli not only directs treatment...
Read More
